Analysts Expect BioCryst Pharmaceuticals, Inc. (BCRX) Will Post Earnings of -$0.28 Per Share

Analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings of ($0.28) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for BioCryst Pharmaceuticals’ earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.33). BioCryst Pharmaceuticals posted earnings per share of ($0.26) in the same quarter last year, which indicates a negative year-over-year growth rate of 7.7%. The firm is scheduled to report its next earnings results on Tuesday, May 14th.

According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full-year earnings of ($1.19) per share for the current fiscal year, with EPS estimates ranging from ($1.30) to ($1.09). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.15) per share, with EPS estimates ranging from ($1.35) to ($0.95). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that cover BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, March 4th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. BioCryst Pharmaceuticals had a negative net margin of 490.25% and a negative return on equity of 175.83%. The business had revenue of $2.73 million during the quarter, compared to analysts’ expectations of $2.39 million.

Several equities analysts recently weighed in on BCRX shares. BidaskClub raised shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, April 3rd. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. Barclays raised their target price on shares of BioCryst Pharmaceuticals from $6.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, April 2nd. Finally, JMP Securities raised their target price on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company a “market outperform” rating in a research note on Tuesday, April 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. BioCryst Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $11.91.

In other BioCryst Pharmaceuticals news, VP Lynne Powell sold 6,000 shares of BioCryst Pharmaceuticals stock in a transaction on Friday, January 25th. The shares were sold at an average price of $9.60, for a total transaction of $57,600.00. Following the completion of the transaction, the vice president now directly owns 6,000 shares of the company’s stock, valued at $57,600. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Thomas R. Staab II sold 5,000 shares of BioCryst Pharmaceuticals stock in a transaction on Monday, January 28th. The stock was sold at an average price of $9.85, for a total transaction of $49,250.00. Following the transaction, the chief financial officer now directly owns 133,426 shares of the company’s stock, valued at $1,314,246.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,500 shares of company stock valued at $308,725. Company insiders own 4.50% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in BCRX. Geode Capital Management LLC lifted its stake in BioCryst Pharmaceuticals by 9.7% in the fourth quarter. Geode Capital Management LLC now owns 1,227,763 shares of the biotechnology company’s stock valued at $9,908,000 after buying an additional 108,785 shares during the period. Amalgamated Bank acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $122,000. Legal & General Group Plc lifted its stake in BioCryst Pharmaceuticals by 14.5% in the fourth quarter. Legal & General Group Plc now owns 19,315 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 2,453 shares during the period. Metropolitan Life Insurance Co. NY lifted its stake in BioCryst Pharmaceuticals by 407.4% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 36,971 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 29,685 shares during the period. Finally, Paloma Partners Management Co acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $84,000. 91.90% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:BCRX traded down $0.83 during midday trading on Friday, hitting $7.52. The stock had a trading volume of 391,975 shares, compared to its average volume of 847,401. BioCryst Pharmaceuticals has a 12 month low of $4.76 and a 12 month high of $9.95. The company has a current ratio of 1.65, a quick ratio of 1.62 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $895.21 million, a PE ratio of -7.67 and a beta of 1.80.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Read More: What are convertible shares? 

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.